InvestorsHub Logo
Followers 1
Posts 59
Boards Moderated 0
Alias Born 01/17/2017

Re: moosedogger post# 12479

Monday, 03/15/2021 9:04:20 PM

Monday, March 15, 2021 9:04:20 PM

Post# of 17479
Dogger - I gave my opinion as an investor.

I would be more concerned if the report misrepresented the capabilities of VOS. Just based on what would be an acceptable price for each drug, the writers appear to be saying that VOS is twice as good as Benalysta. Am I wrong on that assumption?

Like I said - AUPH sales staff will set the doctors straight on the benefits of VOS versus the other drug. Therefore, I have no concern.

Thanks to you and somerssault for bringing this issue to light.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUPH News